Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11925816 | 0.83 | FGFR3 (0.39) | DUTFGFR3KDR | |
| SCHEMBL11925814 | 0.77 | DUT (0.38) | DUT | |
| SCHEMBL2796845 | 0.68 | ALDH1A1 (0.49) | DUT | |
| SCHEMBL25397645 | 0.68 | DUT (0.40) | DUT | |
| SCHEMBL11925813 | 0.67 | DUT (0.42) | DUT | |
| SCHEMBL25251508 | 0.67 | OGA (0.39) | KDRKITOGAQPCT | |
| SCHEMBL18946168 | 0.66 | GRM5 (0.39) | FGFR3KDRKITOGAQPCT | |
| SCHEMBL18946166 | 0.66 | OGA (0.39) | KDRKITOGAQPCT | |
| SCHEMBL14901207 | 0.65 | DUT (0.40) | DUT | |
| SCHEMBL16125131 | 0.65 | DUT (0.40) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796244-B2 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | ASTEX THERAPEUTICS LTD (GB) | 2014-08-05 | — | — | US | disclosed |
| US-8796244-B2 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | ASTEX THERAPEUTICS LTD (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ABL1, ERBB2, RET | DUT 1087/4885FGFR3 82/4885KDR 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.